About US
Contact us
>>Back
Antares, Uman Pharma Partner For Drug Delivery Device Vibex MTX
- Publisher：
- Publication：2010/4/30
Antares Pharma, a provider of self-injection drug delivery technology and Uman Pharma, a manufacturer of injectable pharmaceutical products, have entered into an agreement for the injectable device Vibex.
Under the terms of the agreement Antares and Uman will invest jointly to develop and commercialize Vibex MTX, Antares' new pressure-assisted, injection device, containing methotrexate (MTX) for rheumatoid arthritis and related autoimmune conditions in the US and Canada.
Antares will lead the clinical development program, FDA regulatory submissions, and retains rights to commercialize the Vibex MTX product outside of Canada.
However, Uman is expected to perform formulation development and manufacturing activities to support the registration of Vibex MTX and supply methotrexate in prefilled syringes to Antares for the US market.
Uman has received an exclusive license to commercialise the Vibex MTX product in Canada. The companies plan to work together to commercialise the Vibex MTX product in other territories.
Paul Wotton, president and CEO of Antares, said: "We are pleased to announce this partnership with such a strong partner as Uman Pharma to develop methotrexate for use in our Vibex injection device. We believe that physicians and patients alike will welcome our Vibex injection system for administering parenteral methotrexate."
Sylvain Duvernay, CEO of Uman Pharma, said: "We are very excited and proud to be associated with Antares Pharma for the development and manufacturing of methotrexate in pre-filled syringes and look forward to the anticipated launch of the Vibex delivery technology for the US and Canadian markets.
"Entering this strategic alliance represents an important milestone for us and it is in line with our vision and our mission to bring top-quality products, adding a human touch to make a true difference in patients' lives."
Source:web of PBR